---
document_datetime: 2026-01-05 13:12:42
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/junod-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: junod-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0538445
conversion_datetime: 2026-01-06 07:23:24.727068
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Junod

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 22/12/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300682   | variations.   | Labelling and PL   |
|---------------------|---------------|--------------------|

<div style=\"page-break-after: always\"></div>

|                                       | warning about treatment discontinuation. Following denosumab discontinuation, decrease in bone mineral density (BMD) is expected, leading to an increased risk for fractures. C.I.2.a To update Section 5.1 of the SmPC in order to add new information for pediatric patients as denosumab should not be used for this indication, following the assessment of the same change for the reference product, version dated 18.06.2025.                                                                                                                                                                                                                       |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000313388 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z The in-process limits for hardness are proposed to be widened from 65-85 N to 45-85 N. The lower limits will be at 45N and therefore closer to the limits in the finished product specifications (25-85 N) - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.5 Change to in-process tests or limits | 16/12/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|